Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021
June 03 2021 - 8:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that Michael
Nall, President and CEO, will present at the LD Micro Virtual
Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern
time (12:00 p.m. Pacific time).
“We look forward to providing investors with an update on
CNSide™, our novel assay that provides physicians with a
significantly improved tool to diagnose and manage patients with
tumors that have metastasized to the central nervous system,” said
Mr. Nall. “CNSide’s full commercial launch is now underway with the
potential to provide critical information for the approximately
200,000 patients in the U.S. each year who have progression of
their cancer to the central nervous system.”
Investors and other interested parties can register before
Biocept’s presentation here. Following the presentation, the
webcast will be available on the Company’s website for 90 days.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid (CSF) assay that detects cancer that has
metastasized to the central nervous system. Biocept’s patented
Target Selector™ technology captures and quantitatively analyzes
CSF tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210603005099/en/
Investor Contact: Jody Cain,
LHA Investor Relations Jcain@lhai.com, 310-691-7100
Media Contact: Sampson PR
Group Andrea Sampson asampson@sampsonprgroup.com, (562)
304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2023 to Apr 2024